---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-24-000024"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:07:52.611811+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board

## Summary
- Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.
- Skye Drynan appointed as Class III director; former Capital Group Partner and Senior BioPharma Analyst.
- Each new director receives $40,000 annual cash retainer and option for 230,000 shares vesting over three years.
- Dr. Nathan's guidance intended to support expansion of seralutinib clinical program into PH-ILD.

## SEC filing metadata
- accession: 0001728117-24-000024
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/0001728117-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/goss-20240311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-24-000024
- JSON: https://secwatch.observer/filing/0001728117-24-000024.json
- Plain text: https://secwatch.observer/filing/0001728117-24-000024.txt

## Key facts
- Executive change
  Steven Nathan was appointed as Class I director at Gossamer Bio, Inc..
  - Action: appointed
  - Role: Class I director
  source text: Steven Nathan, M.D. to serve as a Class I director effective March 11, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/0001728117-24-000024-index.htm
- Executive change
  Skye Drynan was appointed as Class III director at Gossamer Bio, Inc..
  - Action: appointed
  - Role: Class III director
  source text: appointed Skye Drynan to serve as a Class III director effective March 11, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000024/0001728117-24-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.